QUVIVIQ (daridorexant) – Europe's first dual orexin

QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact...

Related Keywords

Germany ,Italy ,Canada ,United Kingdom ,Allschwil ,Switzerland General ,Switzerland ,Italian ,Great Britain ,German ,Jean Paul Clozel ,Simon Jose ,Idorsia Ltd ,European Commission Decision Reliance Procedure ,European Union ,European Commission ,Drug Administration ,Health Canada ,Regulatory Agency ,Paul Clozel ,Chief Executive Officer ,Chief Commercial Officer ,Lancet Neurology ,Product Characteristics ,Full Prescribing Information ,Medication Guide ,European Commission Decision Reliance ,Swiss Stock Exchange Idia ,Idorsia Pharmaceuticals Ltd ,